Aripiprazole Tablet
Product Images NDC 62332-098

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 62332-098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole 10

Label for Aripiprazole USP tablets, 10 mg strength, manufactured by Alembic Pharmaceuticals Inc. The label includes the NDC number 62332-099-30, medication name, strength, and a barcode. It also states the tablet count of 30 and storage instructions. The Alembic logo is visible at the bottom.*

FDA Label Image

Aripiprazole 15

The label is for Aripiprazole Tablets USP 15 mg, oral tablets provided by Alembic Pharmaceuticals Inc. It specifies a package size of 30 tablets. The label includes storage instructions, manufacturer details (Alembic Pharmaceuticals Limited, India and Alembic Pharmaceuticals Inc., USA), an NDC code 62332-100-30, barcode, and a note that the medication guide is available. It states the tablets are prescription-only (Rx only).*

FDA Label Image

Aripiprazole 2

Label for Aripiprazole Tablets, USP, 2 mg strength, oral tablet dosage form. The label states the product is manufactured by Alembic Pharmaceuticals Limited (Formulation Division) in Gujarat, India, and distributed by Alembic Pharmaceuticals, Inc. in Bedminster, NJ. It indicates a package size of 30 tablets and includes storage instructions, NDC 62332-097-30, and a barcode. The label also advises pharmacists to dispense with medication guide and notes the product is Rx only.*

FDA Label Image

Aripiprazole 20

The label is for Aripiprazole Tablets, USP, 20 mg, manufactured by Alembic Pharmaceuticals Limited and labeled by Alembic Pharmaceuticals Inc. The package contains 30 oral tablets. It includes storage instructions and a barcode, along with a note to dispense with a medication guide. The label emphasizes the 20 mg strength in a prominent maroon box.*

FDA Label Image

Aripiprazole 30

Aripiprazole Tablets, USP 30 mg label from Alembic Pharmaceuticals Inc. The tablet container holds 30 tablets. Label includes storage instructions, manufacturer information, a barcode, and states 'Pharmacist: Dispense with Medication Guide' and 'Rx only.'*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

A horizontal bar chart showing fold change with 90% confidence intervals for pharmacokinetic (PK) parameters (AUC and Cmax) of various drugs interacting with enzymes CYP2D6, CYP2C9, CYP2C19, and UGT1A4. The x-axis is labeled 'Change Relative to Reference (without interacting drug)' ranging approximately from 0 to 3. Individual drugs include dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, and venlafaxine (along with O-desmethylvenlafaxine). The y-axis displays drug names alongside the measured PK parameters.*

FDA Label Image

Aripiprazole 5

Label for Aripiprazole Tablets, USP 5 mg oral tablets, manufactured by Alembic Pharmaceuticals Inc. The package contains 30 tablets and is labeled Rx only. It includes storage instructions, barcode, and a note to dispense with a medication guide.*

FDA Label Image

Figure 6 (Aripiprazole Fig6)

A Kaplan-Meier curve showing the proportion of relapse over 182 days from randomization in subjects taking Aripiprazole compared to placebo. The graph features two lines, with Aripiprazole showing a lower proportion of relapse than placebo over time. The number of subjects at risk at various time points is listed below the X-axis.*

FDA Label Image

Figure 7 (Aripiprazole Fig7)

A line graph comparing the proportion of subjects with relapse over time for Aripiprazole versus placebo. The x-axis shows days from randomization up to 182 days, and the y-axis represents the proportion with relapse. Two lines represent Aripiprazole (solid) and placebo (dashed), with numbers of subjects at risk listed below the x-axis at various time points.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence interval in AUC and Cmax of dehydro-aripiprazole with various interacting drugs, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam. The x-axis represents change relative to reference without interacting drug.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

Pharmacokinetic chart showing Aripiprazole fold change and 90% confidence intervals for various special populations, including CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment, with axes representing change relative to reference for AUC and Cmax values.*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

A pharmacokinetic fold change chart showing Dehydro-Aripiprazole exposure relative to reference in different populations. Factors compared include CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference (0.5 to 3), with fold change and 90% confidence intervals plotted for AUC and Cmax values.*

FDA Label Image

Structure (Aripiprazole Str)

Chemical structure diagram depicting the molecular structure of aripiprazole, showing rings and functional groups consistent with the active ingredient in the product Aripiprazole tablets by Alembic Pharmaceuticals Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.